Chinese Academy of

IIT2024001 is an active clinical program sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences targeting acute myeloid leukemia (AML), a hematologic malignancy with significant unmet medical need. The program is a small-molecule therapeutic initiative, with its most recent milestone dated August 6, 2025, noting comparative reference to ivosidenib, venetoclax, gilteritinib, and selinexor—all established AML therapies. The program is registered under NCT06265545. While the specific mechanism of action and molecular target for IIT2024001 itself have not been disclosed, the referenced comparator drugs represent key standard-of-care agents: ivosidenib (IDH inhibitor, approved in US, EU, and Australia), venetoclax (Bcl-2 inhibitor, approved across major markets), gilteritinib (FLT3 inhibitor, approved in EU and Australia), and selinexor (XPO1 inhibitor, approved in US, EU, and Australia). The program's phase status, lead investigator, and specific development timeline remain undisclosed. The sponsor's positioning of IIT2024001 alongside these comparators suggests potential competitive positioning within the AML treatment landscape, though the exact therapeutic hypothesis and clinical data remain proprietary at this time.

Acute myeloid leukemia remains a serious hematologic malignancy with significant mortality and morbidity, particularly in elderly and relapsed/refractory populations. The referenced comparator therapies—ivosidenib, venetoclax, gilteritinib, and selinexor—represent major advances in AML treatment, yet each addresses specific molecular subsets or resistance mechanisms. Ivosidenib targets IDH1-mutant AML, venetoclax is used in combination regimens for elderly/unfit patients, gilteritinib addresses FLT3-mutant disease, and selinexor targets nuclear export in resistant disease. The positioning of IIT2024001 alongside these agents by a Chinese Academy of Medical Sciences sponsor suggests potential development of a novel therapeutic addressing an AML subset or resistance pattern. Given the sponsor's institutional affiliation and the active status of the program, this initiative may reflect China's strategic investment in hematologic oncology drug development and the growing clinical trial infrastructure within China. The commercial significance lies in AML's high treatment burden, the aging global population, and the continued need for therapies addressing emerging resistance mechanisms and patient populations not optimally served by existing agents. Market relevance is substantial given the multi-billion-dollar AML therapeutics market and the premium pricing of targeted agents in this indication.

IIT2024001 is classified as a small-molecule therapeutic in active development for acute myeloid leukemia. The specific mechanism of action, molecular target, and route of administration have not yet been disclosed. The program is registered as NCT06265545 and is being conducted by Xiyuan Hospital of China Academy of Chinese Medical Sciences. The most recent milestone (August 6, 2025) references four established AML therapies for comparative context:

• Ivosidenib (TIBSOVO): Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor; oral; approved in US (NDA211192), EU (EMEA/H/C/005056, EMEA/H/C/005936, EMEA/H/C/006174; authorized 24/02/2026), and Australia (PBS code 14868M; listed 01/07/2025)
• Venetoclax (VENCLEXTA): Apoptosis regulator Bcl-2 inhibitor; oral; approved in US (NDA208573), EU (EMEA/H/C/004106; authorized 21/10/2025), and Australia (multiple PBS codes; listed from 01/03/2019)
• Gilteritinib (XOSPATA): Tyrosine-protein kinase receptor FLT3 inhibitor; approved in EU (EMEA/H/C/004752; authorized 27/06/2024) and Australia (PBS codes 13093D, 13094E; listed 01/09/2022)
• Selinexor (XPOVIO): Exportin-1 inhibitor; oral; approved in US (NDA212306), EU (EMEA/H/C/005127; authorized 14/08/2023), and Australia (PBS codes 13085Q, 13086R, 13099K, 13103P, 13104Q, 13105R; listed 01/09/2022)

Patent status and first approval date for IIT2024001 are not yet disclosed.

United States: IIT2024001 regulatory status not yet disclosed. Comparator agents approved: ivosidenib (NDA211192), venetoclax (NDA208573), gilteritinib (not listed in US facts), selinexor (NDA212306).

European Union: IIT2024001 regulatory status not yet disclosed. Comparator agents approved: ivosidenib (EMEA/H/C/005056, EMEA/H/C/005936, EMEA/H/C/006174; authorized 24/02/2026), venetoclax (EMEA/H/C/004106; authorized 21/10/2025), gilteritinib (EMEA/H/C/004752; authorized 27/06/2024), selinexor (EMEA/H/C/005127; authorized 14/08/2023).

Australia: IIT2024001 regulatory status not yet disclosed. Comparator agents approved: ivosidenib (PBS code 14868M; listed 01/07/2025), venetoclax (multiple PBS codes; listed from 01/03/2019), gilteritinib (PBS codes 13093D, 13094E; listed 01/09/2022), selinexor (PBS codes 13085Q, 13086R, 13099K, 13103P, 13104Q, 13105R; listed 01/09/2022).

China (NMPA): IIT2024001 regulatory status not yet disclosed. Comparator agents in clinical trials: venetoclax (NCT04965493, NCT05144243, NCT06386302, NCT06449482, NCT06536010), selinexor (NCT04562870, NCT06449482).

Japan (PMDA): Regulatory status not yet disclosed for IIT2024001 or comparator agents.

Expected loss-of-exclusivity dates for all referenced drugs are not yet disclosed.

Strategic Positioning: IIT2024001 represents Xiyuan Hospital's entry into the AML drug development space, leveraging institutional affiliation with the China Academy of Chinese Medical Sciences. The August 2025 milestone referencing four established comparators (ivosidenib, venetoclax, gilteritinib, selinexor) suggests the program may be positioned to address a specific unmet need within AML—potentially a molecular subset, a resistance mechanism, or a patient population (e.g., elderly, relapsed/refractory) not optimally served by monotherapies.

Competitive Implications: The comparator selection indicates IIT2024001 is likely a small-molecule inhibitor targeting a distinct pathway or molecular driver in AML. The absence of disclosed mechanism and target suggests either early-stage development or proprietary positioning. If successful, IIT2024001 could compete with existing agents in specific AML subsets or in combination regimens. The Chinese sponsor affiliation suggests initial focus on Chinese regulatory approval and patient populations, with potential for international expansion if clinical data support competitive advantages.

Future Catalysts: Key catalysts include: (1) disclosure of IIT2024001's mechanism of action and molecular target; (2) clinical trial initiation or advancement of NCT06265545; (3) interim or final efficacy and safety data; (4) regulatory interactions with NMPA (China) or other authorities; (5) potential partnerships or licensing agreements with international pharmaceutical companies; (6) comparative clinical data versus existing AML therapies.

Expected Milestones: Specific timelines are not yet disclosed. Standard development milestones would include phase advancement, interim data readouts, regulatory submissions, and potential approvals. The active status and recent milestone suggest ongoing development activity, though the phase, enrollment status, and expected data readout dates remain proprietary.